Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/chemoprevention-of-prostate-cancer-krn6wacGQu
References (47)
-
R. Pruthi, E. Derksen, K. Gaston (2003)
Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review.The Journal of urology, 169 6
-
James Hébert, T. Hurley, B. Olendzki, J. Teas, Yunsheng Ma, J. Hampl (1998)
Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study.Journal of the National Cancer Institute, 90 21
-
K. Brusselmans, E. Schrijver, W. Heyns, G. Verhoeven, J. Swinnen (2003)
Epigallocatechin‐3‐gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cellsInternational Journal of Cancer, 106
-
Omer Kucuk, F. Sarkar, W. Sakr, Z. Djuric, Michael Pollak, F. Khachik, Yi Li, M. Banerjee, D. Grignon, J. Bertram, J. Crissman, E. Pontes, D. Wood (2001)
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 10 8
-
A. Krishnan, D. Peehl, D. Feldman (2003)
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expressionJournal of Cellular Biochemistry, 88
-
L. Denis, M. Morton, K. Griffiths (1999)
Diet and Its Preventive Role in Prostatic DiseaseEuropean Urology, 35
-
R. Severson, A. Nomura, J. Grove, G. Stemmermann (1989)
A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii.Cancer research, 49 7
-
G. Andriole, D. Bostwick, O. Brawley, L. Gomella, M. Marberger, D. Tindall, S. Breed, M. Somerville, R. Rittmaster (2004)
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.The Journal of urology, 172 4 Pt 1
-
G. Goodman, Steve Schaffer, G. Omenn, Chu Chen, I. King (2003)
The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 12 6
-
J. Unger, M. LeBlanc, I. Thompson, C. Coltman (2004)
The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.Urologic oncology, 22 4
-
Ronald Lieberman, Jacob Kagan, Margaret House, Joseph Kelaghan, David Kansal, Howard Parnes (1999)
Strategies for chemoprevention of prostate cancerProstate Cancer and Prostatic Diseases, 2
-
H. Adlercreutz, H. Honjo, A. Higashi, T. Fotsis, E. Hämäläinen, T. Hasegawa, H. Okada (1991)
Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet.The American journal of clinical nutrition, 54 6
-
C. Lazier, L. Thomas, R. Douglas, J. Vessey, R. Rittmaster (2004)
Dutasteride, the dual 5α–reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell lineThe Prostate, 58
-
E. Klein (2004)
Selenium: epidemiology and basic science.The Journal of urology, 171 2 Pt 2
-
K. Hastak, Sanjay Gupta, N. Ahmad, M. Agarwal, M. Agarwal, H. Mukhtar (2003)
Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cellsOncogene, 22
-
J. Stanford, J. Stanford, Ziding Feng, A. Hamilton, Frank Gilliland, Frank Gilliland, R. Stephenson, J. Eley, P. Albertsen, L. Harlan, A. Potosky (2000)
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.JAMA, 283 3
-
Lun-yin Yu, G. Blackburn, Jin-Rong Zhou (2003)
Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells.The Journal of nutrition, 133 2
-
E. Klein, S. Lippman, I. Thompson, P. Goodman, D. Albanes, P. Taylor, C. Coltman (2003)
The Selenium and Vitamin E Cancer Prevention TrialWorld Journal of Urology, 21
-
T. Thompson, G. Wilding (2003)
Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.Molecular cancer therapeutics, 2 8
-
Jeffrey Smith, D. Freije, J. Carpten, H. Grönberg, Jianfeng Xu, S. Isaacs, M. Brownstein, G. Bova, Hongguang Guo, P. Bujnovszky, D. Nusskern, J. Damber, Anders Bergh, M. Emanuelsson, O. Kallioniemi, Jennifer Walker‐Daniels, J. Bailey-Wilson, T. Beaty, D. Meyers, P. Walsh, F. Collins, J. Trent, W. Isaacs (1996)
Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide SearchScience, 274
-
L. Clark, G. Combs, B. Turnbull, E. Slate, D. Chalker, J. Chow, L. Davis, R. Glover, G. Graham, E. Gross, A. Krongrad, J. Lesher, H. Park, B. Sanders, Cameron Smith, J. Taylor (1996)
Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled TrialJAMA, 276
-
S. Raghow, Massoumeh Hooshdaran, S. Katiyar, M. Steiner (2002)
Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.Cancer research, 62 5
-
T. Hussain, Sanjay Gupta, H. Mukhtar (2003)
Cyclooxygenase-2 and prostate carcinogenesis.Cancer letters, 191 2
-
R. Hoffman, Frank Gilliland, D. Penson, S. Stone, W. Hunt, A. Potosky (2004)
Cross‐sectional and longitudinal comparisons of health‐related quality of life between patients with prostate carcinoma and matched controlsCancer, 101
-
D. Bodiwala, C. Luscombe, M. French, Samson Liu, M. Saxby, Peter Jones, S. Ramachandran, A. Fryer, R. Strange (2003)
Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type.Carcinogenesis, 24 4
-
J. Ni, Ming Chen, Yu Zhang, Rongshan Li, Jiaoti Huang, S. Yeh (2003)
Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.Biochemical and biophysical research communications, 300 2
-
T. Hedlund, W. Johannes, G. Miller (2003)
Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitroThe Prostate, 54
-
Tara Vogt, R. Ziegler, B. Graubard, C. Swanson, R. Greenberg, J. Schoenberg, G. Swanson, R. Hayes, S. Mayne (2003)
Serum selenium and risk of prostate cancer in U.S. blacks and whitesInternational Journal of Cancer, 103
-
U. Obermüller-Jevic, E. Olano-Martín, A. Corbacho, J. Eiserich, A. Vliet, G. Valacchi, C. Cross, L. Packer (2003)
Lycopene inhibits the growth of normal human prostate epithelial cells in vitro.The Journal of nutrition, 133 11
-
E. Giovannucci (1999)
Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature.Journal of the National Cancer Institute, 91 4
-
S. Shappell, S. Olson, S. Hannah, S. Manning, R. Roberts, N. Masumori, M. Jisaka, W. Boeglin, V. Vader, D. Dave, M. Shook, T. Thomas, C. Funk, A. Brash, R. Matusik (2003)
Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.Cancer research, 63 9
-
Sarah Landis, Taylor Murray, Sherry Bolden, P. Wingo (1999)
Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 49
-
Longwen Chen, M. Stacewicz‐Sapuntzakis, Claudine Duncan, Roohollah Sharifi, Luna Ghosh, R. Breemen, David Ashton, Phyllis Bowen (2001)
Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention.Journal of the National Cancer Institute, 93 24
-
A. Schulman (1999)
Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention -
Yunqian Pan, Jin-San Zhang, Mozammel Gazi, C. Young (2003)
The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 12 8
-
J. Virtamo, P. Pietinen, J. Huttunen, P. Korhonen, N. Malila, M. Virtanen, D. Albanes, P. Taylor, P. Albert (2003)
Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up.JAMA, 290 4
-
M. Steiner, S. Raghow (2003)
Antiestrogens and selective estrogen receptor modulators reduce prostate cancer riskWorld Journal of Urology, 21
-
S. Harlan, M. Cooperberg, E. Elkin, D. Lubeck, M. Meng, S. Mehta, P. Carroll (2003)
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.The Journal of urology, 170 5
-
C. Rodríguez, M. McCullough, A. Mondul, E. Jacobs, Dorna Fakhrabadi-Shokoohi, E. Giovannucci, M. Thun, E. Calle (2003)
Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 12 7
-
John Gillespie (2003)
Journal ReviewInternational Society of Hair Restoration Surgery, 13
-
L. Cohen, Zhonglin Zhao, B. Pittman, J. Scimeca (2003)
Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R‐3327‐AT‐1 rat prostate tumorsThe Prostate, 54
-
F. Civantos, M. Soloway, J. Pinto (1996)
Histopathological effects of androgen deprivation in prostatic cancer.Seminars in urologic oncology, 14 2 Suppl 2
-
E. Klein, F. Meyskens (2001)
Potential target populations and clinical models for testing chemopreventive agents.Urology, 57 4 Suppl 1
-
B. Carter, G. Bova, T. Beaty, Gary Steinberg, B. Childs, W. Isaacs, P. Walsh (1993)
Hereditary prostate cancer: epidemiologic and clinical features.The Journal of urology, 150 3
-
E. Klein, C. Tangen, P. Goodman, S. Lippman, I. Thompson (2005)
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
-
Gerald Andriole, C. Roehrborn, Claude Schulman, K. Slawin, M. Somerville, R. Rittmaster (2004)
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.Urology, 64 3
-
A. Potosky, J. Legler, P. Albertsen, J. Stanford, Frank Gilliland, A. Hamilton, J. Eley, R. Stephenson, L. Harlan (2000)
Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.Journal of the National Cancer Institute, 92 19
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2006 by Annual Reviews. All rights reserved
- ISSN
- 0066-4219
- eISSN
- 1545-326X
- DOI
- 10.1146/annurev.med.57.121304.131435
- pmid
- 16409136
- Publisher site
- See Article on Publisher Site
Abstract
Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-related morbidity, long latency between premalignant lesions and clinically evident cancer, and defined molecular pathogenesis. The Prostate Cancer Prevention Trial has provided the first firm evidence that this cancer can be prevented by a relatively nontoxic oral agent. Additional agents, many of which are antioxidants with antiandrogenic effects, are being tested (or soon will be) in large clinical trials. The current body of evidence is insufficient to make a routine recommendation of any dietary or nutritional supplement for the prevention of prostate cancer.
Journal
Annual Review of Medicine – Annual Reviews
Published: Feb 18, 2006